Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Bristol-Myers’ New Cancer Medication Costs Blockbuster $142,000 Per Year

December 3, 2015 - The newest multiple myeloma cancer treatment developed by Bristol-Myers Squibb – Empliciti – in collaboration with AbbVie, won US Food and Drug Administration (FDA) approval on Monday.

Breast Cancer Gene BRCA1 Implicated In Alzheimer’s Disease

December 2, 2015 - The BRCA1 protein is found in lower than normal levels in the brains of people with Alzheimer’s disease, leading the researchers to postulate that a lack of the protein in neurons may lead to abnormal brain function and cognitive impairment indicative of the disease

Teva and Takeda Partner To Meet Demand For Generics In Japan

December 2, 2015 - Yesterday, Teva Pharmaceutical Industries Ltd. and Takeda Pharmaceutical Company Limited announced their intention to form a partnership, with a focus on providing generics to the Japanese market.

Has your company already registered as an outsourcing facility under the FDA’s section 503B? Or do you plan on keeping your designation as a compounding pharmacy? Share your thoughts in the comments section below!


Is Your Clinical Trial Ready For An FDA Inspection? Surprising Insights Gained From An Interview With An Inspection Trainer

Copyright © 2016-2017 Honeycomb Worldwide Inc.